NASDAQ:PEPG

PepGen (PEPG) Stock Forecast, Price & News

$16.20

+0.47 (+2.99%)

(As of 01:33 PM ET)

Compare

Today's Range: $15.40
▼
$16.20
50-Day Range: $9.27
▼
$16.26
52-Week Range: $4.32
▼
$20.00

Volume: 52,916 shs
Average Volume: 43,914 shs
Market Capitalization: $385.24 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $27.00

PepGen MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 71.6% Upside
$27.00 Price Target
Short Interest: Healthy
1.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.30
Based on 3 Articles This Week
Insider Trading: Selling Shares
$44,742 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.29) to ($3.34) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

505th out of 981 stocks

Pharmaceutical Preparations Industry

241st out of 483 stocks

3.5

Analyst's Opinion

Consensus Rating
PepGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $27.00, PepGen has a forecasted upside of 71.6% from its current price of $15.73.
Amount of Analyst Coverage
PepGen has only been the subject of 2 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.08% of the float of PepGen has been sold short.
Short Interest Ratio / Days to Cover
PepGen has a short interest ratio ("days to cover") of 5.2.
Change versus previous month
Short interest in PepGen has recently decreased by 5.62%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
PepGen does not currently pay a dividend.
Dividend Growth
PepGen does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PEPG.

0.9

News and Social Media Coverage

News Sentiment
PepGen has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for PepGen this week, compared to 1 article on an average week.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PepGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $44,742.00 in company stock.
Percentage Held by Insiders
Only 3.97% of the stock of PepGen is held by insiders.
Percentage Held by Institutions
71.47% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for PepGen are expected to decrease in the coming year, from ($3.29) to ($3.34) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PepGen is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PepGen is -4.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
PepGen has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About PepGen (NASDAQ:PEPG) Stock

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Receive PEPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter.

PEPG Stock News Headlines

June 8, 2023 | americanbankingnews.com

James G. Mcarthur Sells 1,800 Shares of PepGen Inc. (NASDAQ:PEPG) Stock

May 31, 2023 | msn.com

Wedbush Reiterates PepGen (PEPG) Outperform Recommendation

June 8, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 31, 2023 | finance.yahoo.com

PepGen (PEPG) Down on Clinical Hold for DM1 Candidate

May 30, 2023 | marketwatch.com

PepGen Shares Tumble 18.4% After FDA Issues Hold Notice on Study

May 30, 2023 | finance.yahoo.com

PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

May 19, 2023 | seekingalpha.com

PepGen gets Health Canada nod to start trial of PGN-EDO51 for DMD

May 18, 2023 | finance.yahoo.com

PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy

June 8, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 16, 2023 | americanbankingnews.com

PepGen Inc. (NASDAQ:PEPG) Expected to Earn FY2027 Earnings of $0.29 Per Share

May 16, 2023 | americanbankingnews.com

Equities Analysts Set Expectations for PepGen Inc.'s Q1 2024 Earnings (NASDAQ:PEPG)

May 12, 2023 | msn.com

HC Wainwright & Co. Reiterates PepGen (PEPG) Buy Recommendation

May 12, 2023 | marketwatch.com

10-Q: PEPGEN INC.

May 11, 2023 | de.investing.com

PepGen: EPS übertrifft Schätzungen um 0,14$ - Umsatz wie erwartet

May 11, 2023 | msn.com

PepGen: Q1 Earnings Insights

May 11, 2023 | finanznachrichten.de

PepGen Inc.: PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 11, 2023 | finance.yahoo.com

PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 4, 2023 | finance.yahoo.com

PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference

April 30, 2023 | americanbankingnews.com

Short Interest in PepGen Inc. (NASDAQ:PEPG) Declines By 13.0%

April 17, 2023 | finance.yahoo.com

PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting

April 13, 2023 | finance.yahoo.com

PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference

April 3, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on PepGen Inc. (PEPG)

April 3, 2023 | americanbankingnews.com

PepGen (NASDAQ:PEPG) Stock Rating Reaffirmed by HC Wainwright

March 27, 2023 | finance.yahoo.com

PepGen Inc. (NASDAQ:PEPG) Q4 2022 Earnings Call Transcript

March 27, 2023 | americanbankingnews.com

PepGen (NASDAQ:PEPG) Earns "Buy" Rating from HC Wainwright

March 27, 2023 | americanbankingnews.com

PepGen (NASDAQ:PEPG) Price Target Raised to $22.00 at Wedbush

March 23, 2023 | benzinga.com

PepGen Stock (NASDAQ:PEPG), Dividends

See More Headlines

PEPG Price History

30 days | 90 days | 365 days | Advanced Chart

PEPG Company Calendar

Last Earnings: 5/11/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PEPG
CUSIP: N/A
CIK: 1835597
Web: www.pepgen.com
Phone: 781-797-0979
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $27.00
High Stock Price Forecast: $33.00
Low Stock Price Forecast: $22.00
Forecasted Upside/Downside: +71.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,100,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -35.94%
Return on Assets: -31.33%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.35
Quick Ratio: 9.35

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.60 per share
Price / Book: 2.07

Miscellaneous

Outstanding Shares: 23,780,000
Free Float: 22,838,000
Market Cap: $374.06 million
Optionable: Not Optionable
Beta: N/A

Key Executives

Dr. James G. McArthur Ph.D. (Age 61)
Pres, CEO, Treasurer, Sec. & Director
Comp: $597.95k

Ms. Caroline Godfrey Ph.D.
Founder & Scientific Advisory Board Member

Mr. Noel Donnelly M.B.A. (Age 53)
Chief Financial Officer
Comp: $519.65k

Dr. Jaya Goyal Ph.D. (Age 55)
Exec. VP of Research & Preclinical Devel.
Comp: $558.4k

Dr. Michael Gait
Founder & Scientific Advisory Board Member

Dr. Sonia Bracegirdle DPHIL (Age 37)
Sr. VP of Strategy & Operations

Ms. Jennifer Cormier
Sr. VP of Clinical Operations

Dr. Michelle L. Mellion M.D. (Age 47)
Sr. VP & Head of Clinical Devel.

Mr. Niels Svenstrup Ph.D. (Age 53)
Sr. VP of Chemistry, Manufacturing & Control

Mr. Kyle Breidenstine
VP of Fin. & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PEPG Stock - Frequently Asked Questions

Should I buy or sell PepGen stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PepGen in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PEPG shares.
View PEPG analyst ratings or view top-rated stocks.
What is PepGen's stock price forecast for 2023?: 3 analysts have issued 1-year price objectives for PepGen's stock. Their PEPG share price forecasts range from $22.00 to $33.00. On average, they anticipate the company's share price to reach $27.00 in the next twelve months. This suggests a possible upside of 71.6% from the stock's current price.
View analysts price targets for PEPG or view top-rated stocks among Wall Street analysts.
How have PEPG shares performed in 2023?: PepGen's stock was trading at $13.37 at the beginning of the year. Since then, PEPG stock has increased by 17.7% and is now trading at $15.73.
View the best growth stocks for 2023 here.
When is PepGen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our PEPG earnings forecast.
How were PepGen's earnings last quarter?: PepGen Inc. (NASDAQ:PEPG) posted its quarterly earnings data on Thursday, May, 11th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.10.
What ETFs hold PepGen's stock?: ETFs with the largest weight of PepGen (NASDAQ:PEPG) stock in their portfolio include Direxion mRNA ETF (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Invesco DWA SmallCap Momentum ETF (DWAS), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB),

When did PepGen IPO?: (PEPG) raised $126 million in an initial public offering (IPO) on Friday, May 6th 2022. The company issued 9,000,000 shares at $13.00-$15.00 per share.
What is PepGen's stock symbol?: PepGen trades on the NASDAQ under the ticker symbol "PEPG."
Who are PepGen's major shareholders?: PepGen's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (10.98%), BlackRock Inc. (4.15%), Geode Capital Management LLC (1.02%), State Street Corp (0.87%), Bank of New York Mellon Corp (0.17%) and Charles Schwab Investment Management Inc. (0.16%). Insiders that own company stock include James G Mcarthur and Jaya Goyal.
View institutional ownership trends.
How do I buy shares of PepGen?: Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is PepGen's stock price today?: One share of PEPG stock can currently be purchased for approximately $15.73.
How much money does PepGen make?: PepGen (NASDAQ:PEPG) has a market capitalization of $374.06 million. The company earns $-69,100,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis.
How can I contact PepGen?: The official website for the company is www.pepgen.com. The company can be reached via phone at 781-797-0979 or via email at investors@pepgen.com.

This page (NASDAQ:PEPG) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial